Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The possible benefit of prophylactic antibiotic use in patients undergoing unilateral elective inguinal hernia repair with prosthetic material.
ISRCTN ISRCTN85660082
ClinicalTrials.gov identifier
Public title The possible benefit of prophylactic antibiotic use in patients undergoing unilateral elective inguinal hernia repair with prosthetic material.
Scientific title Prospective randomized controlled trial on the use of single dose antibiotic prophylaxis in patients undergo unilateral elective primary inguinal hernia repair with standard polypropylene mesh.
Acronym N/A
Serial number at source N/A
Study hypothesis Tension-free repairs with prosthetic materials has lowered the recurrence rates in inguinal hernia repairs. As a foreign material polypropylene mesh may increase surgical site infection rate in early and late period. Some prospective randomised studies were done in this subject to reveal the benefit of antibiotic prophylaxis in these operations. However, no consensus does exist and every institution runs its own protocol to manage the cases.
Lay summary
Ethics approval Diskapi Teaching and Research Hospital Ethics Committee approved on the 24th of June 2009 (ref: 0016)
Study design Prospective interventional double blind randomised active controlled trial.
Countries of recruitment Turkey
Disease/condition/study domain inguinal hernia; surgical site infection; wound infection
Participants - inclusion criteria 1. Patients with primary unilateral hernia
2. Patients undergo unilateral primary hernia repair with a previously repaired or leave for interval repair on the contralateral side.
3. Age greater than 18 years, both female and male
Participants - exclusion criteria 1. Patients undergo simultaneous bilateral hernia repair
2. Patients with newly diagnosed or uncontrolled diabetes mellitus
3. Patients who do not accept the registry and randomisation
4. Incarcerated or strangulated hernias requiring emergency repair
5. Known severe coagulation disorder
6. Patients who use aspirin, clopidogrel (Plavix®) or warfarin (Coumadin®)
7. Recurrent hernias
Anticipated start date 01/07/2009
Anticipated end date 30/06/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet. (in Turkish)
Target number of participants 200
Interventions Eligible patients will be randomised by using sealed envelopes (equally numbered) to the control arm (no antibiotic prophylaxis) or to the intervention arm (antibiotic prophylaxis). The patients in the intervention arm will receive single dose intravenous cefazolin at the induction of anaesthesia. No topical antibiotic or antiseptic agents will be used within the surgical field after the repair is completed. No patients in either group will be given any additional antibiotic postoperatively. Dressings put in the operation room will be changed on day 1 and totally removed on day 3. Control examination for infection follow-up will take place on day 1, day 3, day 7 and day 30. The late surgical site infection rates will be measured after one postoperative year for each patient and will be announced in a further report.
Primary outcome measure(s) Surgical site infection:
1. Superficial infection
2. Deep infection
Secondary outcome measure(s) Components of the primary outcome:
1. Day of infection first recognised
2. Microbial culture for identification of the microorganism
3. Therapeutic antibiotic regimen according to antibiogram results
4. Final result for the wound and prosthetic material
Sources of funding Diskapi Teaching and Research Hospital (Turkey) - Department of Surgery
Trial website
Publications
Contact name Prof  Hakan  Kulacoglu
  Address Bahcelievler, 1.cadde, 109/5
  City/town Ankara
  Zip/Postcode 06490
  Country Turkey
  Email hakankulacoglu@hotmail.com
Sponsor Diskapi Teaching and Research Hospital (Turkey)
  Address c/o Hakan Kulacoglu, MD, FACS,
Associate Professor of Surgery
Department of Surgery
  City/town Ankara
  Zip/Postcode 06000
  Country Turkey
  Email hakankulacoglu@hotmail.com
  Sponsor website: http://www.diskapieah.gov.tr/english.htm
Date applied 21/01/2010
Last edited 04/03/2010
Date ISRCTN assigned 04/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central